Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke

Journal of Alzheimer's Disease

Volumn 2, Issue 3-4, 2000, Pages 199-206

  Hesse, Camilla ^a   Rosengren, Lars ^a   Vanmechelen, Eugeen ^b   Vanderstichele, Hugo ^b   Jensen, Christer ^a   Davidsson, Pia ^a   Blennow, Kaj ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b INNOGENETICS   (Belgium)

Author keywords

Alzheimer's disease; Amyloid (1 42); Apolipoprotein E; Cerebral infarction; Cerebrospinal fluid(CSF); Stroke; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; HUMAN; NERVE CELL LESION; PRIORITY JOURNAL; TIME;

EID: 0034487623     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2000-23-402     Document Type: Article

References (23)

1. Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
2. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
3. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease
4. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
5. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
6. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
7. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
8. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
9. Isoform-specific binding of apolipoprotein E to beta-amyloid
10. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease
11. Immunohistochemical characteri-zation of alterations in the distribution of amyloid precursor proteins and beta-amyloid peptide after experimental brain injury in the rat
12. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: Correlations with amyloid load in the brain
13. Detection of single amyloid beta protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy
14. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
15. Pathobiology of traumatically induced axonal injury in animals and man
16. Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid
17. The occult aftermath of boxing
18. Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease
19. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neorofilament protein in CSF
20. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids
21. Apolipoprotein E and Alzheimer's disease
22. Isoform-specific interactions of apolipoprotein E with microtubule- associated protein tau: Implications for Alzheimer disease
23. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease